1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’

Adjunctive Studies Will Continue

 
• By Andrew McConaghie

An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.

Brain cloud jigsaw
After years of no new therapies, major depressive disorder is seeing advances again. • Source: Shutterstock

Relmada Therapeutics’s hopes of bringing new major depressive disorder drug REL-1017 to market have been knocked after the failure of its Phase III monotherapy study, where the results were undermined by strong improvements seen in the placebo arm.

The news also drove the micro-cap company’s NASDAQ-listed shares off a cliff, its stock losing 80% of its value and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

More from Therapy Areas